Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors of

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Apr 26

PMID 38667041

Authors

Zoe Masset

Sathursha Gunaratnam

Mathieu Millette

Lynne V McFarland

Monique Lacroix

Affiliations

Soon will be listed here.

Abstract

infections (CDIs) continue to be a persistent healthcare concern despite newer antibiotic treatments, enhanced infection control practices, and preventive strategies focused on restoring the protective intestinal microbial barrier. Recent strides in gene sequencing research have identified many genes regulating diverse virulence factors for CDIs. These genes may be over- or under-expressed when triggered by various environmental and nutritional factors. The aims of this paper are to review the important genes involved in pathogenesis and to identify modifiable environmental, nutritional, and other factors that may trigger the expression of these genes and thus offer new strategies to prevent CDIs.

References

Antunes A, Martin-Verstraete I, Dupuy B . CcpA-mediated repression of Clostridium difficile toxin gene expression. Mol Microbiol. 2011; 79(4):882-99. DOI: 10.1111/j.1365-2958.2010.07495.x. View

Taggart M, Snelling W, Naughton P, La Ragione R, Dooley J, Ternan N . Biofilm regulation in Clostridioides difficile: Novel systems linked to hypervirulence. PLoS Pathog. 2021; 17(9):e1009817. PMC: 8428550. DOI: 10.1371/journal.ppat.1009817. View

Stewart D, Hegarty J . Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. J Med Microbiol. 2013; 62(Pt 10):1517-1523. DOI: 10.1099/jmm.0.059709-0. View

Moradi M, Mansouri S, Nakhaee N, Sarafzadeh F, Zarandi E . Toxin A and B genes expression of in the sub-minimum inhibitory concentration of clindamycin, vancomycin and in combination with ceftazidime. Iran J Microbiol. 2020; 12(1):18-24. PMC: 7163043. View

Su G, Ko C, Bercik P, Falck-Ytter Y, Sultan S, Weizman A . AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020; 159(2):697-705. DOI: 10.1053/j.gastro.2020.05.059. View

Masset Z, Gunaratnam S, Millette M, McFarland L, Lacroix M . Transcriptome analysis of the Clostridioides difficile response to a specific lactobacilli probiotic formulation: explanations for its mechanisms of action. J Appl Microbiol. 2023; 134(3). DOI: 10.1093/jambio/lxad047. View

Guglielmetti S, Mora D, Gschwender M, Popp K . Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011; 33(10):1123-32. DOI: 10.1111/j.1365-2036.2011.04633.x. View

Konkel M, Tilly K . Temperature-regulated expression of bacterial virulence genes. Microbes Infect. 2000; 2(2):157-66. DOI: 10.1016/s1286-4579(00)00272-0. View

Saund K, Pirani A, Lacy D, Hanna P, Snitkin E . Strain Variation in Clostridioides difficile Cytotoxicity Associated with Genomic Variation at Both Pathogenic and Nonpathogenic Loci. mSphere. 2022; 7(3):e0017422. PMC: 9241522. DOI: 10.1128/msphere.00174-22. View

10.

Mikamo H, Tateda K, Yanagihara K, Kusachi S, Takesue Y, Miki T . Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. J Infect Chemother. 2018; 24(9):744-752. DOI: 10.1016/j.jiac.2018.05.010. View

11.

McFarland L, Ship N, Auclair J, Millette M . Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. J Hosp Infect. 2018; 99(4):443-452. DOI: 10.1016/j.jhin.2018.04.017. View

12.

Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, Di Masi A . Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects. Toxins (Basel). 2016; 8(5). PMC: 4885049. DOI: 10.3390/toxins8050134. View

13.

Martin J, Mawer D, Wilcox M . Clostridium difficile: biological therapies. Curr Opin Infect Dis. 2013; 26(5):454-60. DOI: 10.1097/01.qco.0000433319.82618.8f. View

14.

Deneve C, Bouttier S, Dupuy B, Barbut F, Collignon A, Janoir C . Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. Antimicrob Agents Chemother. 2009; 53(12):5155-62. PMC: 2786344. DOI: 10.1128/AAC.00532-09. View

15.

Liu C, Monaghan T, Yadegar A, Louie T, Kao D . Insights into the Evolving Epidemiology of Infection and Treatment: A Global Perspective. Antibiotics (Basel). 2023; 12(7). PMC: 10376792. DOI: 10.3390/antibiotics12071141. View

16.

Karlsson S, Dupuy B, Mukherjee K, Norin E, Burman L, Akerlund T . Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infect Immun. 2003; 71(4):1784-93. PMC: 152060. DOI: 10.1128/IAI.71.4.1784-1793.2003. View

17.

Sniffen J, McFarland L, Evans C, Goldstein E . Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018; 13(12):e0209205. PMC: 6306248. DOI: 10.1371/journal.pone.0209205. View

18.

Shen J, Mehrotra D, Dorr M, Zeng Z, Li J, Xu X . Genetic Association Reveals Protection against Recurrence of Infection with Bezlotoxumab Treatment. mSphere. 2020; 5(3). PMC: 7203456. DOI: 10.1128/mSphere.00232-20. View

19.

Webb B, Brunner A, Lewis J, Ford C, Lopansri B . Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent Clostridioides difficile Infection. Clin Infect Dis. 2018; 68(3):498-500. DOI: 10.1093/cid/ciy568. View

20.

Gu H, Shi K, Liao Z, Qi H, Chen S, Wang H . Time-resolved transcriptome analysis of Clostridium difficile R20291 response to cysteine. Microbiol Res. 2018; 215:114-125. DOI: 10.1016/j.micres.2018.07.003. View